Related Experiment Video
Updated: Jul 17, 2026
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
A Dual-Responsive Claringbullite-Like Nanozyme for Inhibition of Non-Small Cell Lung Cancer Progression
Xu Chen1, Tianle Yang1, Wenjie Zheng2
1Life Sciences Institute, Guangxi Medical University, Nanning, China.
Small Methods
|July 16, 2026
Summary
A novel nanozyme, FCN, targets non-small cell lung cancer (NSCLC) by selectively inducing tumor cell death. This dual-responsive material also enhances anti-tumor immunity and reduces metastasis, offering a new therapeutic avenue.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide.
- Developing targeted therapies with minimal side effects is crucial for improving patient outcomes.
- Nanozymes offer promising catalytic properties for cancer treatment.
Purpose of the Study:
- To fabricate and characterize a novel Claringbullite-like nanozyme, CuCl0.38F0.1(OH)1.51•nH2O (FCN).
- To evaluate the efficacy of FCN as a targeted therapeutic agent for non-small cell lung cancer (NSCLC).
- To investigate the underlying mechanisms of FCN-mediated anti-tumor effects and immune responses.
Main Methods:
- A simple "one-pot" synthesis method was employed to fabricate the FCN nanozyme.
- The pH/GSH dual-responsive "AND" logic gate property of FCN was utilized for selective tumor targeting.
- In vitro studies on A549 cells assessed FCN's catalytic activities (CAT, POD, GPx-like), ROS generation, and effects on cellular metabolism.
- In vivo studies in mice bearing Lewis lung carcinoma (LLC) cells evaluated FCN's therapeutic efficacy and anti-metastatic potential.
Main Results:
- FCN demonstrated enhanced catalytic activity in H2O2 decomposition due to improved charge transfer.
- FCN selectively targeted tumor cells, inducing cuproptosis and ferroptosis by depleting glutathione (GSH), increasing reactive oxygen species (ROS), and inhibiting glycolysis.
- FCN treatment promoted anti-tumor immune responses, including M1 macrophage polarization, increased CD8+ T cells, and decreased regulatory T (Treg) cells.
- FCN significantly reduced lung metastasis in a mouse model.
Conclusions:
- The FCN nanozyme exhibits potent anti-cancer properties for NSCLC treatment through multi-modal mechanisms.
- FCN's dual-responsive nature ensures targeted therapy with minimized side effects.
- This study highlights the potential of metal-halide nanozymes as a novel platform for cancer catalytic therapy.
